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Abstract
Background: Treatment response biomarkers are urgently needed for castration-
resistant prostate cancer (CRPC). Baseline and post-treatment circulating tumor cell
(CTC) counts of 5 cells/7.5 ml are associated with poor CRPC outcome.
Objective: To determine the value of a 30% CTC decline as a treatment response
indicator.
Design, setting, and participants: We identiﬁed patients with a baseline CTC count
5 cells/7.5 ml and evaluable post-treatment CTC counts in two prospective trials.
Intervention: Patients were treated in the COU-AA-301 (abiraterone after chemothera-
py) and IMMC-38 (chemotherapy) trials.
Outcome measures and statistical analysis: The association between a 30% CTC
decline after treatment and survival was evaluated using univariable and multivariable
Cox regression models at three landmark time points (4, 8, and 12 wk). Model perfor-
mance was evaluated by calculating the area under the receiver operating characteristic
curve (AUC) and c-indices.
Results: Overall 486 patients (122 in IMMC-38 and 364 in COU-AA-301) had a CTC count
5 cells/7.5 ml at baseline, with 440, 380, and 351 patients evaluable at 4, 8, and 12 wk,
respectively. A 30% CTC decline was associated with increased survival at 4 wk (hazard
ratio [HR] 0.45, 95% conﬁdence interval [CI] 0.36–0.56; p < 0.001), 8 wk (HR 0.41, 95% CI
0.33–0.53; p < 0.001), and 12 wk (HR 0.39, 95% CI 0.3–0.5; p < 0.001) in univariable and
multivariable analyses. Stable CTC count (<30% fall or<30% increase)was not associated
with a survival beneﬁt when compared with increased CTC count. The association
between a 30% CTC decline after treatment and survival was independent of baseline
CTC count. CTC declines signiﬁcantly improved the AUC at all time-points. Finally, in the
COU-AA-301 trial, patients with CTC 5 cells/7.5 ml and a 30% CTC decline had similar
overall survival in both arms.* Corresponding author. Pr
Trust, Section of Medicine,
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Conclusions: A 30% CTC decline after treatment from an initial count 5 cells/7.5 ml
is independently associated with CRPC overall survival following abiraterone and chemo-
therapy, improving the performance of a multivariable model as early as 4 wk after
treatment. This potential surrogate must now be prospectively evaluated.
Patient summary: Circulating tumor cells (CTCs) are cancer cells that can be detected in the
blood of prostate cancer patients. We analyzed changes in CTCs after treatment with
abiraterone and chemotherapy in two large clinical trials, and found that patients who
have a decline in CTC count have a better survival outcome.
# 2016 European Association of Urology. Published by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Prostate cancer is the second most common malignancy in
men, and the fifth leading cause of death from cancer
worldwide [1]. Although initially responsive to androgen
deprivation, lethal castration-resistant prostate cancer
(CRPC) ultimately develops. In recent years, unprecedented
advances in drug development for CRPC have been observed
with the approval of abiraterone, enzalutamide, cabazitaxel,
and radium [2–7].
One of the greatest challenges in the current manage-
ment of CRPC is adequate assessment of response to
treatment. A significant proportion of patients present with
disease exclusively in bone, which is not amenable to
evaluation by the commonly used Response Evaluation
Criteria in Solid Tumors (RECIST). Consensus Prostate
Cancer Working Group 2 (PCWG2) criteria [8] rely on bone
scintigraphy and changes in prostate-specific antigen (PSA)
levels to evaluate response to treatment in these patients.
Progression according to bone scintigraphy is not evaluable
before 16 wk because of the possibility of spurious flare
reactions [9], so a confirmatory scan is required after a first
scan indicating progression. Likewise, evaluation of pros-
tate-specific antigen (PSA) values for progression is not
recommended before 12 wk of treatment. Most studies
evaluating PSA declines as a surrogate of survival have
yielded negative results [10–12] and treatment discontinu-
ation based solely on rising PSA values is not recommended
[8]. Recent studies have reported a stronger association
between radiological progression-free survival (rPFS) and
overall survival (OS); however, a definition of progression
according to rPFS cannot currently be acquired before at
least 12–16 wk of treatment, and is difficult to evaluate in
men with widespread bone involvement [13]. Improved
biomarkers to identify patients not benefitting from
anticancer treatment are urgently needed.
Enumeration of the circulating tumor cell (CTC) count
has emerged as a powerful biomarker for evaluating
prognosis and treatment response in CRPC. The utility of
the CellSearch assay (Janssen Diagnostics, Raritan, NJ, USA)
in classifying counts into unfavorable (5 cells/7.5 ml)
and favorable (4 cells/7.5 ml) prognostic groups has
been proven in prospective trials including IMMC-38,
COU-AA-301, AFFIRM, and SWOG-S0421 [14–19]. Associa-
tion between post-treatment CTC changes and CRPC
survival has been reported in terms of CTC conversion
(change from unfavorable at baseline to favorable or vice
versa) [14], fold-change in CTC [17], and a 30% CTC decline
from baseline [16], and it has been shown that CTC counthas superior performance to other circulating biomarkers
including PSA. CTCs have also been evaluated as a surrogate
endpoint in several prospective trials. In the COU-AA-301
trial, a composite biomarker panel comprising CTC and
lactate dehydrogenase (LDH) at 12 wk after treatment
satisfied the Prentice criteria for surrogacy at the individual
patient level [20]. It is envisaged that validation of these
results in further prospective clinical trials could contribute
to testing trial-level surrogacy so that CTC counts could
become a clinical trial endpoint to accelerate drug approval
for advanced CRPC.
We carried out a post hoc analysis of data for patients in
the prospective IMMC-38 (chemotherapy) and COU-AA-301
(abiraterone) trials with baseline CTC 5 cells/7.5 ml,
evaluating the value of a 30% CTC decline from baseline
at 4, 8, and 12 wk as a biomarker of response to treatment.
2. Patients and methods
2.1. Study population and procedures
We performed a post hoc analysis of the COU-AA-301 and IMMC-
38 trials. COU-AA-301 was a phase 3 trial in which postchemotherapy
patients with metastatic CRPC were randomly assigned to abiraterone
and prednisone or placebo and prednisone. IMMC-38 was a prospective,
open-label study in patients withmetastatic CRPC undergoing treatment
with chemotherapy. Details of the methodology and the ﬁnal results for
both trials have been published elsewhere [2,14,21]. Both studies were
approved by local institutional boards. All patients provided written
informed consent before participation. CTC counts were measured
at baseline and on day 1 of cycle 2 (weeks 4–5), day 1 of cycle 3 (weeks
8–9), and day 1 of cycle 4 (weeks 12–13) in the COU-AA-301 trial. In the
IMMC-38 trial, CTC counts were measured in weeks 2–5 (median 4 wk),
weeks 6–8 (median 7 wk), and weeks 9–12 (median 11.9 wk). All CTC
countsweremeasured using the CellSearch assay [22]. Hemoglobin (Hb),
alkaline phosphatase (ALP), albumin (ALB), and LDH concentrations
were measured at baseline and at each study visit. Eastern Cooperative
Oncology Group performance status (ECOG-PS) was recorded at
baseline. PSA levels were measured every 4 wk in IMMC-38 and every
12 wk in COU-AA-301.
2.2. Statistical analysis
Kaplan-Meier analysis was used to estimate survival. Univariable and
multivariable Cox proportional hazards models were used to test the
association between the response biomarker and survival. Logistic
regression models were used to calculate odds ratios (ORs). Post-
treatment CTC response was deﬁned as a 30% decline from baseline at 4,
8, and 12 wk from treatment initiation. A landmark analysis was used to
explore the association between CTC response and survival, and speciﬁc
4-, 8- and 12-week populations were deﬁned (Supplementary Fig. 1).
Table 1 – Baseline characteristics for the whole trial population
All patients COU-AA-301 IMMC-38
Patients (n) 486 364 122
CTC count (cells/7.5 ml) 19.5 (9–43.8) 18 (9–38.5) 24 (10–97)
PSA (ng/ml) 214.4 (69–579) 197.3 (64.8–570) 244 (90–604)
ALP (U/l) 216 (121–385.5) 205.5 (116–401.5) 231 (129.8–363.8)
LDH (U/l) 263 (199.3–389.5) 267 (199.5–384.8) 250 (199.3–404.8)
Hemoglobin (g/dl) 11.4 (10.3–12.5) 11.2 (10.2–12.4) 11.8 (10.8–12.9)
Albumin (g/dl) 3.9 (3.6–4.2) 4 (3.7–4.2) 3.7 (3.4–4)
ECOG PS, n (%)a
0–1 419 (87.3) 315 (86.5) 104 (89.7)
2 61 (12.7) 49 (13.5) 12 (10.3)
CTC = circulating tumor cell; PSA = prostate-speciﬁc antigen; ALP = alkaline phosphatase; LDH = lactate dehydrogenase; ECOG PS = Eastern Cooperative
Oncology Group performance status.
a Six missing baseline ECOG PS values in the IMMC-38 data set.
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three different time points; p values were considered statistically
signiﬁcant if p < 0.0167. Baseline LDH, ALP, PSA, and CTC data were log-
transformed because of positively skewed distributions. The overall
performance of the survival models was evaluated by calculating
receiver operating characteristic (ROC) curves for 6- and 11-mo survival
endpoints (approx. themedian and third survival quartile of the data set)
and the c-index for each model using the method proposed by Uno et al
[23]. The area under the ROC curve (AUC) was compared by calculating
the U statistic (nonparametric) [24]. Bootstrapping techniques were
used to calculate the 95% conﬁdence interval (CI) of the difference
between c-indices. Analyses were performed using SPSS v21 (SPSS Inc.,
Chicago, IL, USA) and the R statistics package v3.2.1 (R Foundation,
Vienna, Austria).
3. Results
Overall, 486 patients with baseline CTC 5 cells/7.5 ml
participating in the IMMC-38 (n = 122) and COU-AA-301
(n = 364) trials were included in the analysis. The patient
inclusion criteria are presented in a CONSORT diagram in
Supplementary Figure 1). An analysis of patients with
baseline CTC <5 cells/7.5 ml, who had significantly better
outcome compared to patients with CTC 5 cells/7.5 ml
(Supplementary Fig. 2), will be published separately. The
median follow-up was 11.2 mo (10.2 mo in IMMC-38;
11.3mo in COU-AA-301). At the time of analysis, 360 (74.1%)
patients had died, with median OS of 11.6 mo (95% CI 10.3–
12.8). ThemedianOS for patientswith baseline CTC5 cells/
7.5 ml was comparable between IMMC-38 (11.5 mo, 95% CI
9.8–13.2) and COU-AA-301 (11.7 mo, 95% CI 10.3–13.1). The
median baseline CTC was 19.5 cells/7.5 ml (24 in IMMC-38
and 18 in COU-AA-301). Other baseline characteristics are
summarized in Table 1 and Supplementary Table 1.
To define the most appropriate response cutoff, we
initially compared the performance of 30% and 50% CTC
declines. A 30% cutoff was chosen because of its higher
sensitivity in comparison to a 50% CTC decline (Supple-
mentary Tables 2 and 3).
3.1. A 30% CTC response is associated with survival benefit
Overall, 283 (64.3%), 248 (65.3%), and 226 (64.4%) patients
experienced a 30% decline in CTC count at 4, 8, and 12 wk,respectively (Table 2). A 30% CTC decline was associated
with better survival at 4 wk (14.4 vs 7.9 mo; HR 0.45, 95% CI
0.36–0.56; p < 0.001), 8 wk (15.4 vs 7.9 mo; HR 0.41, 95% CI
0.33–0.53; p < 0.001), and 12 wk (16.1 vs 9.7 mo; HR 0.39,
95% CI 0.3–0.5; p < 0.001). The associationwas consistent in
both the COU-AA-301 and IMMC-38 data sets (Table 2). A
30% CTC decline was associated with survival in multivari-
able analysis. In addition to a 30% CTC decline, baseline CTC
count, and baseline LDH were associated with survival
across all three landmark populations (Supplementary
Table 4).
Addition of a 30% CTC decline to multivariable survival
models significantly enhanced the AUC and c-indices.
Addition of baseline CTC count to a multivariable model
comprising baseline PSA, LDH, ALB, Hb, ALP, and ECOG PS
increased the c-index marginally (0.681 at 4 wk, 0.658 at
8 wk, and 0.669 at 12 wk). Addition of a 30% CTC decline
to the model caused a more pronounced increase in
the c-index to 0.72 at 4 wk and 0.71 at 8 and 12 wk.
Likewise the ROC curves (6- and 11-mo mortality
endpoints) showed a significant increase in AUC when a
30% CTC decline was added to the models (Fig. 1).
Some 113/486 patients (23.1%) achieved a confirmed
50% PSA response. PSA response was significantly associated
with a 30%CTCdecline at 4wk (OR14.8;p < 0.001), 8wk (OR
18; p < 0.001), and 12 wk (OR 13.6; p < 0.001) in both the
COU-AA-301 and IMMC-38 populations (Supplementary
Table 5).
3.2. CTC response and treatment arm in the COU-AA-301 trial
Of the 364 COU-AA-301 trial participants in the analysis,
245 (67.3%) received abiraterone + prednisone and 119
(32.7%) received placebo + prednisone; the abiraterone
cohort had better OS (13.8 vs 9.5 mo; HR 0.75, 95% CI
0.58–0.96; p = 0.02). This benefit was maintained across all
three landmark survival populations (Fig. 2), confirming
that abiraterone provided a significant survival benefit
in patients with baseline CTC 5 cells/7.5 ml. Overall,
162 (73.3%) patients receiving abiraterone + prednisone
and 46 (43.4%) patients receiving prednisone + placebo had
a 30% CTC decline, confirming the intrinsic antitumor
activity of prednisone. Treatment arm was not significantly
Table 2 – Association between survival and CTC responsea
n (%) Median OS, mo
(95% CI)
HR (95% CI)b p valueb
Week 4
All patients 440 11.4 (10.5–12.4)
Response 283 (64.3) 14.4 (12.8–15.9) 0.45 (0.36–0.56) <0.001
Non-response 157 (35.7) 7.9 (6.9–8.9)
IMMC-38 113 11.2 (9.7–12.6)
Response 75 (66.4) 12.3 (8.2–16.3) 0.46 (0.29–0.74) 0.001
Non-response 38 (33.6) 6.8 (4.4–9.2)
COU-AA-301 327 11.7 (10.3-13.1)
Response 208 (63.6) 14.4 (13.2–15.5) 0.44 (0.34–0.57) <0.001
Non-response 119 (36.4) 7.9 (6.9–9)
Week 8
All patients 380 12.5 (11.1–13.9)
Response 248 (65.3) 15.4 (13.9–16.8) 0.41 (0.33–0.53) <0.001
Non-response 132 (34.7) 7.9 (15.4–12.5)
IMMC-38 84 12.3 (9.4–15.1)
Response 56 (66.7) 17.2 (9.7–24.6) 0.42 (0.24–0.74) 0.003
Non-response 28 (33.3) 10.2 (5.5–14.9)
COU-AA-301 296 12.6 (11.1–14.2)
Response 192 (64.9) 15.4 (14.1–16.7) 0.4 (0.31–0.53) <0.001
Non-response 104 (35.1) 7.7 (6.7–8.5)
Week 12
All patients 351 13.8 (12.3–15.3)
Response 226 (64.4) 16.1 (14.6–17.7) 0.39 (0.3–0.5) <0.001
Non-response 125 (35.6) 9.7 (8.3–11.1)
IMMC-38 79 13.6 (10.6–16.6)
Response 55 (69.6) 18.2 (11.7–24.7) 0.35 (0.19-0.63) <0.001
Non-response 24 (30.4) 13.6 (10.6–16.6)
COU-AA-301 272 13.9 (12.2–15.6)
Response 171 (62.9) 15.9 (14.5–17.4) 0.41 (0.3–0.54) <0.001
Non-response 101 (37.1) 9.7 (7.7–11.7)
CTC = circulating tumor cell; OS = overall survival; HR = hazard ratio; CI = conﬁdence interval.
a Response was deﬁned as a 30% decline in CTC count relative to baseline at each of the landmark time points.
b Univariable Cox regression.[(Fig._1)TD$FIG]
Fig. 1 – Receiver operating characteristic (ROC) curves for three models at (A) 4 wk, (B) 8 wk, and (C) 12 wk. Model 1 comprised CTC response, baseline
CTC (log-transformed), baseline LDH (log-transformed), and baseline ECOG status at 4 wk; and CTC response, baseline CTC (log-transformed), and
baseline LDH (log-transformed) at 8 and 12 wk. Model 2 comprised baseline CTC (log-transformed), baseline LDH (log-transformed), and baseline ECOG
status at 4 wk; and baseline CTC (log-transformed) and baseline LDH (log-transformed) at 8 and 12 wk. Model 3 comprised baseline LDH
(log-transformed) and baseline ECOG status at 4 wk; and baseline LDH (log-transformed) at 8 and 12 wk. CTC = circulating tumor cell; LDH = lactate
dehydrogenase; ECOG = Eastern Cooperative Oncology Group; AUC = area under the ROC curve.
* Status variable: survival at 11 mo (yes vs no).
** Comparison of two correlated ROC curves (De Long’s rest) with model 1 as the reference model.
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Table 3 – Effect of treatment arm on multivariable models with and without CTC response in the COU-301 trial
Model without CTC responsea Model with CTC responseb
HR (95% CI) p value HR (95% CI) p value
Week 4 0.65 (0.49–0.84) 0.001 0.87 (0.65–1.17) 0.352
Week 8 0.65 (0.49–0.86) 0.003 0.9 (0.66–1.24) 0.529
Week 12 0.73 (0.53–0.98) 0.041 0.86 (0.63–1.18) 0.360
CTC = circulating tumor cell; HR = hazard ratio for treatment arm (abiraterone vs placebo); CI = conﬁdence interval.
a Model includes: treatment arm; baseline CTC count (log-transformed); lactate dehydrogenase (log-transformed); albumin; alkaline phosphatase
(log-transformed); hemoglobin; prostate-speciﬁc antigen (log-transformed); and Eastern Cooperative Oncology Group performance status.
b Model includes: 30% CTC response at 4, 8, or 12 wk; treatment arm; baseline CTC count (log-transformed); lactate dehydrogenase (log-transformed); albumin;
alkaline phosphatase (log-transformed); hemoglobin; prostate-speciﬁc antigen (log-transformed); and Eastern Cooperative Oncology Group performance status.
[(Fig._2)TD$FIG]
Fig. 2 – Survival in COU-AA-301 according to treatment arm and CTC response at (A) 4 wk, (B) 8 wk, and (C) 12 wk. Blue lines denote data for patients
who received abiraterone + prednisone and red lines patients who received placebo + prednisone. Continuous lines indicate patients with a CTC
response and dotted lines patients with no CTC response. CTC = circulating tumor cell; OS = overall survival; CI = confidence interval; Abi = abiraterone;
resp = response.
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included in the model. Furthermore, interaction tests
between treatment arm and a 30% CTC decline were not
significant (p = 0.758), suggesting an equivalent survival
benefit for abiraterone and prednisone or prednisone alone
in post-chemotherapy patients who achieved a 30% CTC
decline (Table 3).
3.3. Stable CTC count and CTC conversion
We investigated the utility of a stable CTC count, defined as
a change from baseline that did not exceed a 30% decline or
a 30% increase, at each of the prespecified time points.
Overall, 57 (13%), 43 (11.3%), and 42 (12%) patients
experienced a stable CTC count at 4, 8 and 12 wk,
respectively. A 30% CTC decline showed a significant OS
benefit when compared to a stable CTC count at all time
points, but no difference was observed when comparing
stable and progressive (>30% increase) CTC counts (Fig. 3).
Overall, 165 (37.5%), 193 (44.3%), and 154 (43.9%)
patients achieved conversion to a favorable CTC count of
<5 cells/7.5 ml at 4, 8, and 12 wk, respectively. Patients
achieving such CTC conversion also had a significant OSbenefit at all time points studied (Supplementary Table 6).
We compared AUC values for CTC conversion and 30% CTC
response (6-mo OS) among all patients and among patients
with baseline CTC 10 and 30 cells/7.5 ml (Supplementa-
ry Table 7). Although the AUC was consistently higher for a
30% CTC decline than for CTC conversion, no significant
differences were found except for patients with high
baseline CTC (10 cells/7.5 ml) at 4 wk (AUC 0.701 vs
0.624; p = 0.008).
4. Discussion
The prognostic value of baseline CTC has been evaluated in
a number of studies in which patients received chemo-
therapy [14,17,18] and androgen receptor (AR) signaling
inhibitors [19,20]. The value of a post-treatment change,
defined as the percentage change from baseline in the
manner for other established treatment response biomark-
ers such as PSA decline or a change in diameter of target
lesions (RECIST), has been suggested by our group in a
report on a large single-centre series [16] but has not been
explored in a clinical trial data set to date. This is the first
report to exclusively study patients whose CTC response
[(Fig._3)TD$FIG]
Fig. 3 – Overall survival (OS) according to circulating tumor cell (CTC) response at (A) 4 wk, (B) 8 wk, and (C) 12 wk. The hazard ratio (HR) and 95%
confidence interval (CI) were determines using Cox regression with CTC response as the categorical variable and stable disease as the reference
covariable.
a Stable versus response.
b Stable versus progression.
E U RO P E AN URO LOGY 7 0 ( 2 0 1 6 ) 9 8 5 – 9 9 2990could be evaluated (ie, with baseline CTC 5 cells/5.7 ml),
amounting to approximately 50% of patients with
advanced CRPC (47.2% in COU-AA-301 and 57.9% in
IMMC-38). An analysis of patients with baseline CTC <5
cells/7.5 ml will be published separately.
This pooled post hoc analysis for two prospective clinical
trials shows that a 30% CTC decline as early as 4 wk after
treatment initiation can effectively distinguish between
patients benefiting from improved OS and patients not
benefiting from treatment who may require a switch to an
alternative therapeutic regimen.
We previously reported separate data showing that a
30% CTC decline was associated with improved OS in a
smaller cohort [16]. Using larger prospective series, we now
report that a post-treatment 30% CTC decline is associated
with longer OS in patients treated with abiraterone +
prednisone, corticosteroids alone, and chemotherapy. We
considered the choice of a 30% cutoff for a number of
reasons. When compared with a 50% CTC decline, although
global AUC and c-index values did not differ significantly, a
30% CTC decline was a more sensitive biomarker; a test for
early identification of nonresponders should value sensi-
tivity over specificity to minimize the risk of false negatives
and unnecessary discontinuation of potentially effective
treatments. Likewise, establishing a percentage decline
criterion for response is more sensitive than a conversion
from 5 to <5 cells/7.5 ml. Critically, it is difficult to
consider a patient whose CTC count falls from 100 to 5 cells/
7.5 ml after three cycles as a ‘‘nonresponder’’ while
considering a patient whose CTC count falls from 5 to
4 cells/7.5 ml as a ‘‘responder’’. The CTC threshold of
5 cells/7.5 ml, initially chosen to differentiate patients
with and without cancer (false-positive cells identified
incorrectly as CTCs by detection platforms), has limitations
when estimating disease response. We also found that
patients in whom CTCs do not decrease following treatmenthave similar OS to those whose CTCs rise following
treatment, suggesting that a treatment switch may need
to be considered in both groups.
Importantly, we found that the effect of a post-treatment
CTC decline was equivalent in patients treated with
chemotherapy and AR signaling inhibitors. HR values for
responders participating in the IMMC-38 (chemotherapy)
and COU-AA-301 (abiraterone after chemotherapy) trials
were very similar, which supports the validity of CTC count
as a response biomarker in both treatment groups. The
similar median OS and baseline characteristics of both
populations support the suitability of pooled analysis.
Addition of a 30% CTC post-treatment decline to
multivariable models can provide independent and addi-
tional information on outcome to that provided by baseline
CTC. Addition of a 30% CTC decline to the multivariable
models significantly increased AUC values at all time points
studied.
When analyzing the COU-AA-301 data set separately,
CTC response was able to identify patients with longer
survival in both the abiraterone and prednisone arms of the
study. Although the frequency of a 30% CTC decline was
significantly lower in the prednisone than in the abirater-
one arm of COU-AA-301, patients experiencing a 30% CTC
decline on prednisone had median OS comparable to that
for participants experiencing a CTC response in the
abiraterone arm, and higher than that for nonresponders
who received abiraterone, suggesting that corticosteroids
had antitumor activity in these patients.
Our study has a number of limitations. Although this is
the largest analysis of patients with baseline CTC 5 cells/
7.5 ml, limitations arising from its unplanned post hoc
nature must be acknowledged. Furthermore, only 858/1195
(71.8%) patients enrolled in the COU-AA-301 trial could be
evaluated for CTCs. Although CTCs were investigated until
progression in the IMMC-38 study, these were only
E U RO P E AN URO LOG Y 7 0 ( 2 0 1 6 ) 9 8 5 – 9 9 2 991determined at 4, 8, and 12 wk in the COU-AA-301 study.
Moreover, the value of a stable CTC count was not
investigated in the COU-AA-301 and IMMC-38 data sets
independently owing to a lack of sufficient events. Finally,
although both median OS and baseline characteristics were
similar in the data sets for both trials, approximately
three times as many patients were treated with abiraterone
(COU-AA-301) than with chemotherapy (IMMC-38).
5. Conclusions
In conclusion, we believe that changes in CTCs as early as
4 wk after treatment can identify patients not benefiting
from treatment. Clinical trials are nowunderway to explore
the benefit of a treatment switch in nonresponding patients.
Further prospective phase 3 trials are needed to confirm the
surrogate value of CTC and the CTC-LDH panel already
reported for the COU-AA-301 trial [20]. We envisage that
the clinical qualification of CTC count as a intermediate
endpoint biomarker of OS in advanced prostate cancer may
be close to a positive conclusion.
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